NCT04960709 2026-04-14
VOLGA
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT03924856 2025-08-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03924895 2025-08-28
KEYNOTE-905
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04209114 2024-06-27
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT02845050 2018-02-13
JaNEO
Ligartis GmbH
Phase 1/2 Withdrawn
NCT00490880 2007-06-25
Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer
Eli Lilly and Company
Phase 2 Completed